详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Radiomics diagnosed histopathological growth pattern in prediction of response and 1-year progression free survival for colorectal liver metastases patients treated with bevacizumab containing chemotherapy.

137| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Radiology, Peking University People’s Hospital, 11 Xizhimen South St., Beijing 100044, China [2]School of Life Science and Technology, Xidian University, 266 Xinglong Section of Xifeng Road, Xi’an, Shanxi 710126, China [3]Department of Radiology, West China Hospital of Sichuan University, 37 Guoxue Xiang Street, Chengdu, Sichuan Provence 610041, China [4]Department of Radiology, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou 510655, China [5]Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, 95 Zhongguancun East Road, Beijing 100190, China [6]Beijing Key Laboratory of Molecular Imaging, Beijing 100190, China [7]Department of Medical Oncology, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou 510655, China [8]Department of Gastrointestinal Surgery, Peking University People’s Hospital, 11 Xizhimen South St., Beijing 100044, China [9]Department of Medical Oncology, Cancer Center, West China Hospital of Sichuan University, 37 Guoxue Xiang Street, Chengdu, Sichuan Provence 610041, China [10]Beijing Advanced Innovation Centre for Big Data-Based Precision Medicine, School of Medicine, Beihang University, Beijing 100191, China [11]Engineering Research Centre of Molecular and Neuro Imaging of Ministry of Education, School of Life Science and Technology, Xidian University, Xi’an 710126, China

出处：

DOI：

ISSN：

关键词： Histopathologic growth pattern Colorectal liver metastases Unresectable Radiomics Bevacizumab

摘要：

To investigate the capability of a radiomics model, which was designed to identify histopathologic growth pattern (HGP) of colorectal liver metastases (CRLMs) based on contrast-enhanced multidetector computed tomography (ceMDCT), to predict early response and 1-year progression free survival (PFS) in patients treated with bevacizumab-containing chemotherapy.Patients with unresectable CRLMs who were treated with bevacizumab-containing chemotherapy were included in this multicenter retrospective study. For each target lesion, the radiomics-diagnosed HGP (RAD_HGP) of desmoplastic (D) pattern or replacement (R) pattern was determined. Logistic regression and receiver operating characteristic (ROC) curves were used to assess lesion- and patient-based responses according to morphologic response criteria. One-year PFS was calculated using Kaplan-Meier curves. Hazard ratios for 1-year PFS were obtained through Cox proportional hazard regression analysis.Among 119 study patients, 206 D pattern and 140 R pattern lesions were identified. In patients with multiple lesions, 52 had D pattern, 31 had R pattern, and 36 had mixed (D + R) pattern. The area under the curve value for RAD_HGP in predicting early response was 0.707 for lesion-based analysis and 0.720 for patient-based analysis. Patients with D pattern had a significantly longer PFS than patients with R pattern or mixed pattern (P < 0.001). RAD_HGP was the only independent predictor of 1-year PFS.HGP diagnosed using a radiomics model could be used as an effective predictor of PFS for patients with CRLMs treated with bevacizumab-containing chemotherapy.Copyright © 2021 Elsevier B.V. All rights reserved.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2021]版：

大类 | 2 区医学

小类 | 3 区核医学

最新[2023]版：

大类 | 3 区医学

小类 | 3 区核医学

JCR分区：

出版当年[2021]版：

Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

最新[2023]版：

Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

影响因子： 3.2 最新[2023版] 3.4 最新五年平均 4.531 出版当年[2021版] 4.218 出版当年五年平均 3.528 出版前一年[2020版] 3.3 出版后一年[2022版]

第一作者：

第一作者机构： [1]Department of Radiology, Peking University People’s Hospital, 11 Xizhimen South St., Beijing 100044, China

共同第一作者：

通讯作者：

通讯机构： [5]Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, 95 Zhongguancun East Road, Beijing 100190, China [6]Beijing Key Laboratory of Molecular Imaging, Beijing 100190, China [10]Beijing Advanced Innovation Centre for Big Data-Based Precision Medicine, School of Medicine, Beihang University, Beijing 100191, China [11]Engineering Research Centre of Molecular and Neuro Imaging of Ministry of Education, School of Life Science and Technology, Xidian University, Xi’an 710126, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

Radiomics diagnosed histopathological growth pattern in prediction of response and 1-year progression free survival for colorectal liver metastases patients treated with bevacizumab containing chemotherapy.

文献详情

相关文献